IDLDX Stock Overview
AroCell AB (publ), a vitro diagnostics company, manufactures and sells IVD tests for oncological and bacterial diseases in Sweden. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
IDL Diagnostics AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 0.57 |
| 52 Week High | SEK 0.66 |
| 52 Week Low | SEK 0.35 |
| Beta | 1.21 |
| 1 Month Change | -1.04% |
| 3 Month Change | -2.56% |
| 1 Year Change | 41.79% |
| 3 Year Change | 4.97% |
| 5 Year Change | -73.11% |
| Change since IPO | -82.73% |
Recent News & Updates
Recent updates
Is Now The Time To Look At Buying AroCell AB (publ) (STO:AROC)?
Apr 20
Estimating The Intrinsic Value Of AroCell AB (publ) (STO:AROC)
Feb 27At kr0.45, Is AroCell AB (publ) (STO:AROC) Worth Looking At Closely?
Nov 07We Think AroCell (STO:AROC) Can Afford To Drive Business Growth
Aug 10AroCell (STO:AROC) Is In A Good Position To Deliver On Growth Plans
Apr 18We're Hopeful That AroCell (STO:AROC) Will Use Its Cash Wisely
Jan 03
Shareholder Returns
| IDLDX | SE Life Sciences | SE Market | |
|---|---|---|---|
| 7D | 0.7% | -0.5% | -1.7% |
| 1Y | 41.8% | 8.5% | -3.1% |
Return vs Industry: IDLDX exceeded the Swedish Life Sciences industry which returned 6.4% over the past year.
Return vs Market: IDLDX exceeded the Swedish Market which returned -4.4% over the past year.
Price Volatility
| IDLDX volatility | |
|---|---|
| IDLDX Average Weekly Movement | 9.2% |
| Life Sciences Industry Average Movement | 8.5% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in SE Market | 13.5% |
| 10% least volatile stocks in SE Market | 4.3% |
Stable Share Price: IDLDX has not had significant price volatility in the past 3 months compared to the Swedish market.
Volatility Over Time: IDLDX's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 20 | Anders Hultman | www.arocell.com |
AroCell AB (publ), a vitro diagnostics company, manufactures and sells IVD tests for oncological and bacterial diseases in Sweden. It offers UBC Rapid, a point-of-care test for diagnosis and monitoring of bladder cancer; AroCell TK 210 ELISA, a biomarker for tumor cell; and TUBEX TF, a vitro diagnostic test for detection of acute typhoid fever. The company was formerly known as Xi Bao Research AB and changed its name to AroCell AB (publ) in 2006.
IDL Diagnostics AB (publ) Fundamentals Summary
| IDLDX fundamental statistics | |
|---|---|
| Market cap | SEK 131.31m |
| Earnings (TTM) | -SEK 44.27m |
| Revenue (TTM) | SEK 59.94m |
Is IDLDX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IDLDX income statement (TTM) | |
|---|---|
| Revenue | SEK 59.94m |
| Cost of Revenue | SEK 47.88m |
| Gross Profit | SEK 12.07m |
| Other Expenses | SEK 56.34m |
| Earnings | -SEK 44.27m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
Aug 21, 2025
| Earnings per share (EPS) | -0.19 |
| Gross Margin | 20.13% |
| Net Profit Margin | -73.86% |
| Debt/Equity Ratio | 0% |
How did IDLDX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/28 13:36 |
| End of Day Share Price | 2025/05/28 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
IDL Diagnostics AB (publ) is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Oscar Bergman | Redeye |